NAS:BCTX (Canada)  
BriaCell Therapeutics Corp logo

BriaCell Therapeutics Corp

$ 5.37 -0.57 (-9.6%) 08:08 PM EST
P/E:
At Loss
P/B:
1.87
Market Cap:
$ 78.95M
Enterprise V:
$ 35.87M
Volume:
268.03K
Avg Vol (2M):
475.32K
Also Trade In:
Volume:
268.03K
Market Cap $:
78.95M
PE Ratio:
At Loss
Avg Vol (2-Month):
475.32K
Enterprise Value $:
35.87M
PB Ratio:
1.87
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a Combination Study with Incyte drugs, INCMGA00012, and epacadostat, in advanced breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing and is designed to produce a potent and selective immune response against the cancer of each patient eliminating the time, expense and complex manufacturing logistics associated with immunotherapies.
Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.99
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 33.12
9-Day RSI 29.97
14-Day RSI 33.7
6-1 Month Momentum % -29.7
12-1 Month Momentum % -13

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 126.3
Quick Ratio 126.3
Cash Ratio 121.66

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -206.6
Name Current Vs Industry Vs History
ROE % -31.46
ROA % -30.06
ROIC % -2044.89
ROC (Joel Greenblatt) % -1470.93
ROCE % -30.51

Financials (Next Earnings Date:2022-12-14 Est.)

BCTX's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:BCTX

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -0.898
Beta 0.92
Volatility % 78.5
14-Day RSI 33.7
14-Day ATR ($) 0.417099
20-Day SMA ($) 7.217
12-1 Month Momentum % -13
52-Week Range ($) 4.06 - 12.47
Shares Outstanding (Mil) 15.52

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

BriaCell Therapeutics Corp Filings

Document Form Filing Date
No Filing Data

BriaCell Therapeutics Corp Analysis

Share your research

Headlines

See More
No news.